Although these developments are encouraging, issues with safety validation, standardization, and legal frameworks still exist
Figure VI
Am J Med 105:54S-58S Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C (2004) Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial
WATCH | What WHO's move to back obesity drugs means: What could approval mean for patients Canadians taking GLP-1 medicatiosn for weight loss pay anywhere from $200 to $400 a month, usually out of pocket as many Canadian insurance companies don't cover the medications for obesity
Research shows that GLP-1 medications combined with lifestyle interventions produce stronger outcomes than medication alone